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IMMUNOTHERAPY WITH 
THE USE OF TUMOR- 
INFILTRATING 
LYMPHOCYTES AND 
INTERLEUKIN-2 AS 
ADJUVANT TREATMENT IN 
STAGE III NON-SMALL-CELL 
LUNG CANCER 
A pilot study 
This study assesses the feasibility and toxicity of adoptive immunotherapy with 
tumor infiltrating lymphocytes and recombinant interleukin.2 in 29 patients who 
underwent resection for stage III non-small-cell ung cancer. In five patients 
cultures yielded no growth of tumor infiltrating lymphocytes. In the remaining 24 
patients (stage IIIa, 14 cases; stage IIIb, 10 cases) tumor infiltrating lymphocytes 
were in vitro expanded from surgically obtained tissue samples, including samples 
from both the tumor and surrounding lung. A number of tumor infiltrating 
lymphocytes, ranging from 4 to 70 billion cells, were reinfused intravenously 4 to 6 
weeks after operation. Interleukin-2 wasadministered subcutaneously at escalating 
doses for 2 weeks and then at reduced oses for 2 to 3 months. Median survival was 
14 months, and the 2-year survival was 40%. Three patients remain alive and 
disease-free atmore than 2 years after operation. Two of these patients did not have 
complete resection at thoracotomy. Multivariate analysis showed no correlation 
between the factor of incomplete resection and survival. Intrathoracic recurrence 
without concomitant distant failure was documented in two patients only and none 
of the patients with incomplete resection (12 cases) had relapse within the thorax. 
The present experience demonstrates that adoptive immunotherapy may be applied 
with safety in patients operated on for stage III non-small-cell lung cancer and 
suggests that it can be useful, notably in patients with locally advanced isease. 
(J THORAC CARDIOVASC SURG 1995;109:1212-7) 
Giovanni B. Ratto, MD, a Giovanni Melioli, MD, b Paolo Zino, MD, ° 
Carlo Mereu, MD, b Sandro Mirabelli, MD, a Giovanni Fantino, MD, a 
Marco Ponte, MD, b Paolo Minuti, MD, c Anna Verna, MD, b Paolo Noceti, MD, d 
Elisabetta Tassara, MD, a and Salvatore Rovida, MD, e Genoa, Pietra Ligure, and 
Imperia, Italy 
A doptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and recombinant interleu- 
kin-2 (IL-2) has been shown to be capable of 
mediating the regression of cancer?' 2 Rosenberg2 
demonstrated the efficacy of in vitro-expanded TIL 
cells in metastatic melanoma, and other groups 
obtained similar results in ovarian carcinoma? Pre- 
clinical studies demonstrated that expanded TIL, 
derived from non-small-cell lung cancers (NSCLCs), 
are able to recognize and efficiently lyse autologous 
cancer cells. 4'5 No clinical study investigated the 
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role of adoptive immunotherapy in the treatment of 
NSCLC. Anecdotal reports in patients with unre- 
sectable tumors basically showed no benefit from 
this approach. 6-8 The reasons accounting for such 
lack of efficacy of adoptive immunotherapy could be 
(1) the small number of infused TIL cells with 
respect to the large number of tumor cells or (2) TIL 
activity inhibition by tumor-derived suppressive fac- 
tors. On the basis of these assumptions, we planned 
a pilot study to assess the feasibility and toxicity of 
adoptive immunotherapy in patients who underwent 
resection for stage III NSCLC. 
Patients and methods 
Preoperative assessment included (1) computed tomo- 
graphic (CT) scans of the chest, upper abdomen, and 
brain, (2) bronchoscopy, (3) ultrasonographic scans of the 
liver and adrenal glands, (4) radionuclide bone scan, and 
(5) cervical or left anterior mediastinoscopy, or both, as 
indicated. For ethical concerns, patients with T3 NO-1 
NSCLC or with minimal N2 disease (that is, involvement 
of one single mediastinal nodal site) were not offered 
adoptive immunotherapy, because their disease could be 
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cured by surgical treatment. Inclusion criteria were (1) 
histologically confirmed NSCLC, (2) mediastinoscopy re- 
sults that demonstrated multiple nodal site metastases 
(and excluded contralateral mediastinal involvement), (3) 
cardiopulmonary function adequate for the planned op- 
eration, (4) performance status from 0 to 1 (ECOG/ 
WHO: 0 to 5 classification), (5) normal hematologic, 
renal, and hepatic function, (6) no prior therapy with 
biologic response modifiers (such as interferon or inter- 
leukins), (7) negative serologic test results for human 
immunodeficiency virus and hepatitis B virus antibodies, 
(8) no previous treatment with antineoplastic therapy, and 
(9) no steroid therapy. 
Informed consent was required before patients entered 
the study. Beginning in January 1991, 29 patients with 
stage III NSCLC were scheduled for adjuvant immuno- 
therapy with the use of TIL cells and rIL-2. In 5 patients 
cultures yielded no growth of T IE  The remaining 24 
patients underwent surgical treatment and subsequent 
immunotherapy. Clinical and pathologic data are reported 
in Table I. The resection was classified as complete (R0) 
or microscopically (R1) or macroscopically incomplete 
(R2), according to previous definitions. 9 
TIL preparation and characterization. Tissue samples, 
including samples from both the tumor and surrounding 
lung, were obtained with a sterile technique from the 
surgically removed specimens (median sample weight, 
24 gin). They were immediately processed, according to a 
4 previously described method. In brief, after removal of 
necrotic tissue and apparently normal ung, neoplastic and 
paraneoplastic tissues were dissociated mechanically, in- 
cubated (for 4 hours at 37°C with use of a magnetic 
stirrer) in RPMI 1640 medium (Microbiological Associ- 
ates, Pool Biological Italiana, Milan, Italy) in the presence 
of deoxyribonuclease (Sigma Chemical Co., St. Louis, 
Mo., 0.002%, 100 IU/mg), collagenase type IV (Sigma, 
final dilution 200 IU/ml), hyaluronidase (Sigma, 1500 
U/ml), and gentamicin (16 mg/100 ml). Erythrocytes, 
debris, and dead cells were eliminated with use of a 
Ficoll-Paque discontinuous gradient (Pharmacia, Inc., Pis- 
cataway, N.J.). The cells found in the gradient interface 
(such as lymphocytes, cancer cells, and alveolar macro- 
phages) were washed and placed at 5 × 105 cells/ml in 
complete medium, containing recombinant IL-2 (Proleu- 
kin, Eurocetus, Amsterdam, The Netherlands, 500 IU/ml) 
and phytohemagglutinin (1% vol/vol; Difco Laboratories, 
Inc., Detroit, Mich.), to induce the activation and prolif- 
eration of any viable T IL )  ° Living mononuclear cells, 
including both lymphocytes and cancer cells, were then 
incubated in RPMI 1640 medium, with 10% human AB 
serum and 500 IU/ml of recombinant IL-2. 
When cells reached the concentration of 3 to 4 x 106 
cells/ml, cultures were divided 1:2 in complete medium 
and their expansion allowed to continue. Cancer cells and 
other "nonlymphoid" cells disappeared from positive cul- 
tures in 2 to 3 weeks and a pure population of proliferat- 
ing lymphocytes was obtained. Cultures yielded growth of 
adequate numbers (1 × 109) of TIL cells in more than 
80% of cases. Single cancer cell suspensions were ob- 
tained as described: Neoplastic ells were frozen i  liquid 
nitrogen for further studies or labeled with 5~Cr for 
cytotoxicity tests. 
Table I. Clinical and pathologic data 
Age (yr 4- SD) 60 4- 9 
Male/female 21/3 
Histologic type 
Squamous carcinoma 14 
Adenocarcinoma 8 
Large-cell carcinoma 2 
Stage IIIa 
T2 N2 7 
T3N2 7 
Stage IIIb 
T4 N2 10 
Operation 
Lobectomy 13 
Sleeve lobectomy 2 
Pneumonectomy 9 
Resection group* 
0 12 
1 8 
2 4 
SD, Standard deviation. 
*See text for description of groups. 
Indirect immunofluorescence and flow cytometry were 
used for culture immunophenotype definition. The follow- 
ing monoclonal antibodies were used: CD3 (leu-4, Becton 
Dickinson Inc., Oxnard, Calif.), CD4, CD8, CD19, CD25, 
HLA-DR (T4, T8, and B4, Coulter Corporation, Hialeah, 
Fla.), CD16 (KD1, produced by our laboratory, and 
fluorescein isothiocyanate-labeled antihuman immuno- 
globulin G, Southern Biological Associated, Birmingham, 
Ala.). Lymphocyte cultures (0.05 rot) were incubated with 
a pretitered dilution of monoclonal antibodies for 30 
minutes at 4 ° C, washed, and then incubated with 0.05 ml 
of fluorescein isothiocyanate-labeled antimouse immuno- 
globulin G (Southern Biological Associated) for 30 min- 
utes. Cells were extensively washed, analyzed on an 
EPICS Elite flow cytometer, and the percentages of 
positive cells were calculated. 
Cytolytic activities were studied on different targets. 
Natural killer (NK) activity was evaluated on K562, a 
human erythroleukemic cell line. Lymphokine-activated 
killer (LAK) cell activity was tested on the NK-resistant 
Daudi cell line. Finally, specific lysis was studied on 
autologous and allogenic cells from primary cultures of 
NSCLC. Cells were labeled with Na251CrO4 as de- 
scribed) 1Different effector/target dilutions (ranging from 
50:1 to 1.5:1) were incubated for 4 hours at 37°C and 
specific lysis was calculated. 1~ 
TIL infusion, Four to 6 weeks from the date of opera- 
tion, in vitro-expanded TIL were infused intravenously 
(day 0). Recombinant IL-2 (Proleukin, Eurocetus) was 
administered subcutaneously, asshown in Fig. 1. Antipy- 
retic agents (paracetamol r indomethacin), ranitidine, 
and antiemetics (ondansetron) were given to control 
fever, gastritis, and vomiting. No corticosteroids or anti- 
neoplastic drugs were administered uring treatment. 
Toxicity of recombinant IL-2 administration was scored 
according to World Health Organization criteria. A J1 
patients were treated in general medical wards and none 
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Fig. 1. Recombinant IL-2 (rlL-2) scheduling after infu- 
sion of in vitro-expanded TIL. 
Table II. Characteristics of infused TIL in 24 
patients with NSCLC (mean and range) 
Percent 
Surface phenotype 
CD3+ lymphocytes 95 (91-100) 
CD4+ lymphocytes 39 (5-88) 
CD8+ lymphocytes 49 (18-82) 
CD16 + lymphocytes 0 (0-2) 
CD19+ lymphocytes 0 (0-2) 
CD25 + lymphocytes 52 (39-86) 
HLA-DR+ lymphocytes 80 (59-85) 
Cytolytic properties* 
K562 (NK cell target) 56 (28-100) 
Daudi (LAK cell target) 35 (12-98) 
Autologous NSCLC cells 41 (0-75) 
Allogeneic NSCLC cells 12 (0-31) 
*Percent of lysis was calculated atthe effector/target ratio of 50:1. 
required intensive care unit monitoring. The follow-up 
ranged from 6 to 32 months (median follow-up, 14 
months) and included (1) CT scan of the chest and 
ultrasonographic s an of the upper abdomen every 6 
months and (2) bronchoscopy, bone scan, and CT scan of 
the brain every 12 months. 
Survival was calculated from the date of operation by 
the Kaplan-Meier method. Although the feasibility of the 
overall approach was the study end point, the influence of 
major prognostic factors (listed in Table I) on survival was 
also evaluated (by the Cox test). 
Results 
In eight patients the resection was classified as R1 
because of (1) metastases in the last-removed node 
in the paratracheal or subcarinal region (4 cases), 
(2) extracapsular mediastinal node disease (3 cases), 
and (3) neoplastic infiltration of the aortic resection 
line (1 case). In four patients the resection was 
classified as R2 because of (1) neoplastic infiltration 
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Fig. 2. Survival of patients with stage III NSCLC who 
underwent surgical treatment and adoptive immunother- 
apy, according to completeness of resection. Number of 
patients at risk for each time interval is given in paren- 
theses. 
of the myocardial resection line (2 cases), (2) mul- 
tiple parietal pleural metastases (1 case), and (3) 
tracheal wall infiltration by extracapsular node dis- 
ease (1 case). One subject, in whom supraclavicular 
node metastases developed 8 months after opera- 
tion, underwent lymphadenectomy followed by a 
second adoptive immunotherapy treatment (TIL 
and recombinant IL-2). This patient died 4 months 
after the second TIL infusion. A number of TIL 
cells ranging from 4 to 70 billion cells was obtained. 
Surface phenotype and cytolytic activity of TIL cells 
are shown in Table II. A correlation between the 
cytolytic CDS+ phenotype and the actual cytolytic 
activity of expanded TIL could not be documented. 
There was no correlation between the number of 
infused TIL and the clinical outcome of patients. 
Median survival was 14 months. Three patients 
remain alive and disease free at more than 2 years 
after operation. Two of these long-term survivors 
did not receive complete resection at thoracotomy 
(R2). Fig. 2 illustrates urvival curves of the com- 
plete resection and incomplete resection groups. 
There was no significant difference between the two 
curves. Multivariate analysis confirmed that in pa- 
tients treated with adoptive immunotherapy, the 
factor of incomplete resection had no influence on 
prognosis (coefficient beta, -0.20). Survival was not 
significantly correlated with any of the investigated 
prognostic factors. 
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The sites of disease relapse are depicted in Table 
IlL Despite the locally advanced disease stage, 
intrathoracic recurrence without concomitant dis- 
tant failure was documented in two patients only. In 
particular, none of the patients with incomplete 
resection (R1 and R2) had a relapse within the 
thorax. 
The toxic effects of adoptive immunotherapy 
were due to recombinant IL-2 administration. 
Toxicities were encountered in the course of the 
first 14 days of therapy and gradually resolved 
with continued administration at reduced doses. 
There were no grade IV (World Health Organi- 
zation) toxic events. All patients had fever (higher 
than 38 ° C), chills, malaise, and nausea, which 
were easily managed with appropriate drugs. A 
rise in levels of creatinine (2 cases) or transami- 
nases (1 case), a cutaneous rash (1 case), and 
oliguria and weight increase greater than 10% (2 
cases) returned to normal after reduction of re- 
combinant IL-2 doses. No modification of circu- 
lating white blood cells was observed after the 
infusion of TIL, whereas after recombinant IL-2 
administration an expansion of eosinophils, asso- 
ciated with a rise in the percentage of CD16+ and 
CD25+ cells, was found. 
Discussion 
Very few reports deal with the use of adoptive 
immunotherapy in the treatment of NSCLC. Eight 
patients with advanced, unresectable NSCLC were 
treated with in vitro-expanded TIL cells and con- 
tinuous infusion of recombinant IL-2 by Kradin and 
associates. 6 None of the patients in that report 
responded to the treatment. Recombinant IL-2 with 
LAK cells or continuous infusion of recombinant 
IL-2 alone has been used in 10 patients with dissem- 
inated disease and failed to obtain major re- 
sponses.7, 8 Different explanations could be provided 
for the lack of efficacy of adoptive immunotherapy 
in patients with unresectable NSCLC. TIL cells that 
exhibit in vitro a specific response against autolo- 
gous tumor cells might suffer in vivo from inhibition 
by tumor cell-derived immunosuppressive factors,  
Alternatively, the ratio of tumor cells to TIL cells 
might be so high as to make adoptive immunother- 
apy ineffective. This assumption is supported by a 
study that reported that cytolytic effects can be 
documented only when a number of TIL cells is 
used that is equal to or superior to the number of 
tumor cells. 2 Thus we tested the feasibility and 
toxicity of adoptive immunotherapy in patients who 
Table III. Sites of failure in 24 patients with stage 
III NSCLC who underwent operation followed by 
adoptive immunotherapy 
No. of failures 
Intrathoracic 
Lung 2 
Distant 
Supraclavicular nodes 1 
Brain 5 
Bone 2 
Liver 1 
Adrenals 1 
Intrathoracic and distant 
Lung and bone 1 
Lung and brain 1 
had undergone resection of the primary neoplasm. 
Our experience demonstrated that such an ap- 
proach can be applied without severe toxic effects in 
more than 80% of subjects with stage III NSCLC. 
Prolonged administration of recombinant IL-2 may 
be done with safety, in the outpatient setting, so that 
the potential long-term maintenance of TIL activity 
is ensured. Several studies have shown that such 
recombinant IL-2 scheduling has a clinical efficacy 
comparable with that of the more toxic regi- 
mens. 12-14 Besides its clinical acceptability, contin- 
ued administration of recombinant IL-2 at nontoxic 
doses has been suggested to induce profound and 
prolonged effects on the patient's immune system] 
The 2-year survival in patients undergoing oper- 
ation followed by adoptive immunotherapy was 40% 
and median survival was 14 months. According to 
current data in the literature, the median survival is 
about 12 months for subjects with stage IIIa and 8 
months for subjects with stage IIIb NSCLC treated 
by intensive means) s'16 It should be noted that, in 
our study, patients with T3 N0-1 lesions (stage IIIa), 
whose disease stage has been associated with a 
better prognosis, were excluded. 
Unexpectedly, in the present series, the subset of 
patients with incomplete resections (R1 and R2) 
had an outcome similar to that of patients with 
complete resection. This finding is at variance with 
the results of a previous tudy from our institution 
that demonstrated that patients with stage III 
NSCLC who underwent incomplete resection have a 
prognosis ignificantly worse than that of patients 
with complete resection. 17 In the incomplete resec- 
tion group, median survival was 9.1 months and the 
2-year survival was 14%. These data would suggest 
that reinfused TIL cells are able to recognize and 
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lyse the intrathoracic omponent of the disease. 
Such assumption is supported by the analysis of the 
patterns of NSCLC relapse, revealing a very low 
intrathoracic failure rate after adoptive immuno- 
therapy. In particular, immunotherapy succeeded in
achieving disease control in patients with residual 
cancer. The effectiveness of immunotherapy in de- 
stroying intrathoracic ancer cells could be ex- 
plained by a previous observation from our labora- 
tory. One hundred million 99mTC labeled TIL cells 
were injected intravenously and monitored on the 
routine clinical gamma-camera. Washout analysis of 
the lungs showed that the majority of labeled TIL 
cells were trapped in the lung during the first 24 to 
36 hours after infusion (manuscript in preparation). 
Thus a prolonged contact, within the chest, between 
the large number of infused TIL cells and residual 
cancer cells could be allowed. The reduced TIL 
concentration, once passed into the systemic ircu- 
lation, could explain the minor impact of adoptive 
immunotherapy on distant metastases. Further, we 
have observed that, in vitro, TIL cells have a prom- 
inent LAK activity. Therefore we could suggest that 
the large number of effector cells concentrated in
the lung may destroy cancer cells, independently 
from the presence of the wide spectrum of adhesion 
molecules, essential for the recognition of tumor 
cells in organs different from the lung. 
The mechanisms by which TIL and recombinant 
IL-2 act remain uncertain. The results we have 
obtained, which indicate a lack of correlation be- 
tween the percentage of cytolytic CD8+ cells in- 
fused and clinical response, seem to support the 
activation of local immunologic mechanisms. These 
mechanisms might include the production of lym- 
phokines and the potentiation of antigen presen- 
tation mediated by specific helper T cells. This 
hypothesis supported by a recent study that inves- 
tigated radiolabeled TIL distribution and revealed 
that the majority of TIL cells do not specifically 
move to tumor sites. 6 
In conclusion, the present study shows that adop- 
tive immunotherapy may be applied with safety in 
patients operated on for stage III NSCLC and 
suggests that it can be useful, notably in patients 
with locally advanced disease. However, the pre- 
sented results should be considered with caution, 
because chance findings as a result of the study 
power may not be excluded. A randomized study has 
been planned to assess the effectiveness of adoptive 
immunotherapy as adjuvant reatment. 
The technical assistance of M. Galanti n the prepara- 
tion of this manuscript is gratefully acknowledged. 
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